Sige Gutman, Chair of Mintz’s Life Sciences Litigation Practice, was quoted in an Endpoints News article examining Supreme Court oral arguments on the limits of “skinny label” drug marketing and potential patent infringement liability for generic manufacturers.

In the article, Sige observes that the justices appeared inclined to decide the case narrowly: “Their overall approach to questioning suggests they will take the lightest touch possible in deciding the dispute,” he said, noting that the Court may avoid setting a new evidentiary standard for establishing active inducement of patent infringement.

Source

Endpoints News